Nasdaq nmra.

Neumora Therapeutics Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.Neumora Therapeutics (NASDAQ: NMRA), a biotech company focused on developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s, went public on September 15th with ...Quais ferramentas de análise técnica podem ser usadas para analisar Neumora Therapeutics, Inc.? Confira vários osciladores, médias móveis e outros indicadores técnicos no TradingView.Shares of Neumora Therapeutics (NMRA 0.41%) were down more than 32% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence.

Sep 14, 2023 · 1 Trading Held Add to Watchlist Add to Portfolio Quotes Summary Sep 14, 2023 9:14 am 0 Previous Close $17.00 Key Data Bid Price and Ask Price The bid & ask refers to the price that an investor is... Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) last issued its earnings results on Wednesday, November 1st. The company reported ($1.14) earnings per share for the quarter, missing the ...

VinFast Auto Ltd. (NASDAQ:VFS) gained 13.6% to $12.73 following a report suggesting the company is planning to set up a manufacturing plant in India. Neumora Therapeutics, Inc. (NASDAQ:NMRA ...Oct 10, 2023 · In addition, NMRA-266 (M4R PAM), another drug in development for the treatment of schizophrenia, is viewed as a de-risked asset due to the large market and low entry barriers for this disease.

Neumora Therapeutics, Inc. (NASDAQ:NMRA) as filed to raise $100 million in an IPO of its common stock, according to an SEC S-1 registration statement.US6409791000. Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action ...A Quick Take On Neumora Therapeutics. Neumora Therapeutics, Inc. ( NASDAQ: NMRA) has filed proposed terms to raise $250 million from the sale of its common stock in an IPO, according to an amended ...When is Neumora Therapeutics (NASDAQ:NMRA) reporting earnings? A. Neumora Therapeutics ( NMRA) is scheduled to report earnings on February 15, 2024. The last reported earnings were for reported on ... Successfully completed initial public offering: In September 2023, Neumora completed its initial public offering of its common stock and shares began trading on the Nasdaq Global Select Market under the ticker symbol “NMRA.” Since its inception, Neumora has raised over $850 million to further its mission to confront the ...

Watch Nasdaq's Neumora Therapeutics [NMRA] Rings the Nasdaq Opening Bell on Livestream.com.

Oct 10, 2023 · For Neumora Therapeutics Inc (NASDAQ:NMRA), William Blair initiated coverage, by setting the current rating at Outperform. The stock has a 52-week-high of $17.74 and a 52-week-low of $9.90.

Sep 15, 2023 · Find the latest Earnings Report Date for Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com. Neumora Therapeutics Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. The latest price target for Harmony Biosciences ( NASDAQ: HRMY) was reported by Needham on Wednesday, November 1, 2023. The analyst firm set a price target for 53.00 expecting HRMY to rise to ...Neumora Therapeutics Inc (NASDAQ: NMRA) gained 15.4% to $14.00 in pre-market trading. Neumora Therapeutics recently initiated a Phase 1 single ascending dose / multiple ascending dose study of ...The latest price target for . Neumora Therapeutics (NASDAQ: NMRA) was reported by JP Morgan on Tuesday, October 10, 2023.The analyst firm set a price target for 21.00 expecting NMRA to rise to ...

On Invalid Date, . Neumora Therapeutics (NASDAQ: NMRA) reported Q3 2023 earnings per share (EPS) of -$1.14, up 7.55% year over year. Total Neumora Therapeutics earnings for the quarter were -$53.03 million.In the same quarter last year, Neumora Therapeutics's earnings per share (EPS) was -$1.06.Shares of Neumora Therapeutics (NMRA 0.41%) were down more than 32% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence.Sep 21, 2023 · Investors can buy NMRA even cheaper than Gosebruch did, with shares changing hands as low as $10.01 at last check today -- that's 20.7% under Gosebruch's purchase price. VIDEO: Thursday 9/21 ... Oct 10, 2023 · For Neumora Therapeutics Inc (NASDAQ:NMRA), William Blair initiated coverage, by setting the current rating at Outperform. The stock has a 52-week-high of $17.74 and a 52-week-low of $9.90. CGC. Canopy Growth Corporation Common Shares. $1.275 -0.065 -4.85%. Find the latest SEC Filings data for Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com.NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and other neuropsychiatric disorders. “The initiation of this Phase 1 study is an important step in the development of NMRA-266.

NVDA. NVIDIA Corporation Common Stock. $439.00 -16.81 -3.69%. Find the latest historical data for Nemaura Medical, Inc. Common Stock (NMRD) at Nasdaq.com.

No Data Available. Neumora Therapeutics Inc. Annual stock financials by MarketWatch. View the latest NMRA financial statements, income statements and …It plans to list on the Nasdaq under the ticker symbol "NMRA." J.P. Morgan, BofA Securities, Stifel, Guggenheim Securities, RBC Capital Markets and William Blair are backing the listing. Neumora ...Complete Neumora Therapeutics Inc. stock information by Barron's. View real-time NMRA stock price and news, along with industry-best analysis.Stock analysis for Neumora Therapeutics Inc (NMRA:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Learn more. See all brokers. View live Neumora Therapeutics, Inc. chart to track its stock's price action. Find market predictions, NMRA financials and market news.Home NMRA • NASDAQ Neumora Therapeutics Inc Follow Share $11.92 Nov 24, 5:45:00 PM GMT-5 · USD · NASDAQ · Disclaimer search Compare to Sezzle Inc $10.20 SEZL5.38% WK Kellogg Co $12.15... Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the ...(NASDAQ:NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will · Neumora ...

The latest price target for . Neumora Therapeutics (NASDAQ: NMRA) was reported by JP Morgan on Tuesday, October 10, 2023.The analyst firm set a price target for 21.00 expecting NMRA to rise to ...

14 Sep 2023 ... Home · News; NMRA. Neumora Therapeutics Inc. - NMRA STOCK NEWS. IMPACT. SENTIMENT. 11/27/2023 07:00 AM. NMRA : Nasdaq.

WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced ...NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and other neuropsychiatric disorders. “The initiation of this Phase 1 study is an important step in the development of NMRA-266.Neumora Therapeutics Inc. (NASDAQ: NMRA) grossed $250.1 million in a September initial public offering that was due in part to a drug pipeline that includes an experimental schizophrenia drug that ...Sep 14, 2023 · 1 Trading Held Add to Watchlist Add to Portfolio Quotes Summary Sep 14, 2023 9:14 am 0 Previous Close $17.00 Key Data Bid Price and Ask Price The bid & ask refers to the price that an investor is... The company’s shares trade on the Nasdaq under the stock symbol “NMRA.” Neumora is a new-ish company, having emerged with a $400 million Series A round of financing in 2021 after its initial formation in 2019. But the company’s history goes back further. Neumora represents the combination of five acquisitions, each bringing drug ...Nov 1, 2023 · WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced ... Find the latest Financials data for Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com.Neumora Therapeutics (NASDAQ: NMRA), a biotech company focused on developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s, went public on September 15th with ...View Our Latest Research Report on NMRA. Neumora Therapeutics Price Performance. NASDAQ:NMRA opened at $12.25 on Thursday. The stock has a fifty day simple moving average of $11.42.

Neumora Therapeutics, Inc. Common Stock (NMRA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Canopy Growth Corporation Common Shares. $1.275 -0.065 -4.85%. Neumora Therapeutics, Inc. Common Stock (NMRA) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US ... Neumora Therapeutics, Inc. (NASDAQ:NMRA) has filed proposed terms to raise $250 million from the sale of its common stock in an IPO, according to an amended SEC registration statement.Research Neumora Therapeutics' (Nasdaq:NMRA) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance ...Instagram:https://instagram. best sector to invest nowbest long term etfs for roth irapager duty stockex dividend dates calendar Neumora Therapeutics, Inc. Common Stock (NMRA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. how much is 1921 silver dollar worthtax on mutual funds The latest price target for . Neumora Therapeutics (NASDAQ: NMRA) was reported by JP Morgan on November 8, 2023.The analyst firm set a price target for $20.00 expecting NMRA to rise to within 12 ...Veja a previsão de preço das ações da Neumora Therapeutics, Inc. para 1 ano, feita pelos analistas e compare-a com as mudanças de preço ao longo do tempo para desenvolver … stock price for dollar general Its other product candidates include NMRA-511, NMRA-266, NMRA-NMDA, NMRA-CK1d, NMRA-NLRP3, and NMRA-GCase. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-266 is a positive allosteric modulator of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia and other neuropsychiatric …Shares of Neumora Therapeutics Inc (NASDAQ: NMRA) were trading lower on Tuesday, a month after the company announced its IPO on the NASDAQ exchange. RBC Capital Markets On Neumora Therapeutics.NMRA Profile. Company Profile. Neumora Therapeutics Inc. 490 Arsenal Way. Suite 200. ... Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.